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AbstrACt
Introduction Globally, the prevalence of uncontrolled 
hypertension is high, particularly in low- and middle-
income countries. There is a critical need for strategies to 
improve hypertension control. The early use of a fixed low-
dose combination of three antihypertensive drugs (triple 
pill) has the potential to significantly improve hypertension 
control. The trI ple Pill vs. U sual care M anagement 
for P atients with mild-to- moderate H ypertension 
(TRIUMPH) randomised controlled trial (RCT) is designed 
to test the effects of this strategy compared with usual 
care in patients with mild-to-moderate hypertension. This 
paper reports the protocol of a process evaluation of the 
TRIUMPH RCT. The objectives are to understand factors 
related to implementation of the intervention, mechanisms 
of effect, contextual factors that underpin the effectiveness 
of the triple pill strategy and the potential barriers and 
facilitators to implementing the strategy in clinical practice.
Methods and analysis Face-to-face semistructured 
in-depth interviews with a purposive sample of TRIUMPH 
RCT participants and healthcare professionals in Sri 
Lanka will be conducted. Healthcare professionals will 
include physicians and their staff who were involved 
in conducting the TRIUMPH RCT. Interviewees will be 
recruited sequentially until thematic saturation is achieved. 
Interviews will be audio recorded, transcribed verbatim 
and analysed in NVivo using framework analysis methods.
Ethics and dissemination The TRIUMPH RCT and 
process evaluation have received approval from the 
relevant Ethics Review Committee. All participants will 
be asked to provide written consent before participation. 
Findings from the study will be disseminated through 
publications and conference presentations.
trial registration number ACTRN12612001120864 , 
SLCTR/2015/020 ; Pre-results.
IntrodUCtIon 
High blood pressure (BP) is the number one 
preventable cause of early loss of life world-
wide.1 Consequently, there has been much 
attention on efforts to prevent and treat 
high BP to avert premature deaths. Inter-
ventions that have been tested to improve 
hypertension control range from popula-
tion-wide approaches such as national poli-
cies to reduce salt intake2 to radical and 
individual-based approaches such as renal 
denervation.3 By far, pharmacological treat-
ment has been the most widely tested and is 
one of the most effective individual medical 
approaches to BP control.
A myriad of drugs with distinct and comple-
mentary physiological effects are at the 
disposal of physicians for prescription. Yet 
one in three people treated for hypertension 
have uncontrolled BP (>140/90 mm Hg).1 
The current approach to the pharmacolog-
ical treatment of hypertension commonly 
known as stepped care strategy involves initi-
ation of monotherapy, with treatment inten-
sification (dose uptitration or adding other 
drugs) at subsequent follow-up visits. While 
guidelines recognise that most patients need 
multiple drugs to achieve BP control,4 5 most 
patients receive only monotherapy.6
There are many patient- and provider-re-
lated factors relating to this stepped care 
strategy that might contribute to inadequate 
BP control. For instance, the cost and incon-
venience of multiple clinic visits and treat-
ment modification,7 8 and non-adherence to 
treatment, which is worsened by increasing 
number of drugs9 are major determinants 
strengths and limitations of this study
 ► Multiple sampling strategies to recruit a large num-
ber of interviewees to cover diverse views.
 ► Use of rigorous methods of data collection and anal-
ysis following a standard protocol.
 ► First of its kind study to explore barriers to hyperten-
sion control in Sri Lanka.
 ► Inability to recruit participants who did not attend 
the end of study visit.
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to BP control. In addition, therapeutic inertia, the resis-
tance of prescribers to intensify therapy in the face of 
uncontrolled hypertension, is a recognised problem10 11 
that is difficult to overcome. While fixed-dose combina-
tion (FDC) drugs are promising solutions to such issues,12 
their use in clinical practice is primarily reserved for 
patients already established on multiple treatments, or 
more rarely, in the early stages of treatment for patients 
with markedly elevated BP.4 5
The use of an FDC comprising three antihypertensive 
drugs in low doses (triple pill) as early or initial treatment 
has the potential to significantly improve hypertension 
control. The rationale is based on sound pharmacolog-
ical principles: each drug will act on distinct and major 
physiological pathways of hypertension producing signifi-
cant reduction in BP, and the use of low doses minimises 
adverse effects. Furthermore, its early use will achieve 
faster BP control and obviate the need for multiple clinic 
visits for treatment modification. However, the use of this 
strategy in clinical practice requires a shift in paradigm as 
it entails significant change in the prescribing behaviours 
of doctors, acceptance by the patients and regulatory 
approval. High quality evidence of its effectiveness and 
the reasons for its success or failure are needed.
The TRIUMPH trial is a parallel-group, open-label, 
randomised controlled trial (RCT) designed to test the 
effectiveness of early use of triple pill compared with 
usual care for the management of hypertension.13 14 In 
brief, patients from multiple outpatient clinics in Sri 
Lanka, with mild-to-moderate hypertension, either naïve 
to BP lowering drugs or receiving monotherapy were to 
be randomised to treatment with triple pill or continued 
usual care, for a period of 6 months. The primary outcome 
of the TRIUMPH RCT is improvement in the proportion 
of people with BP control. Secondary outcomes include 
reduction in BP, improvement in adherence and improve-
ment in quality of life. The TRIUMPH RCT has recruited 
700 participants.
While an RCT assesses the effects of intervention on 
predefined outcomes, a process evaluation helps to 
understand aspects of delivery and receipt of interven-
tion, why and how the intervention worked, influence 
of the settings in which the intervention was delivered 
and potential barriers and facilitators to implementing 
the intervention into clinical practice.15 Additionally, a 
process evaluation can help formulate hypotheses leading 
to further analyses of data from the RCT.
This paper presents the protocol for the process evalua-
tion of a pragmatic RCT of a strategy of initial or early use 
triple pill compared with usual care for the management 
of hypertension among adults in Sri Lanka.
MEtHods And AnAlysIs
A logic model summarising the public health problem, 
evidence, resources, activities and anticipated outcomes 
of TRIUMPH study is depicted in figure 1. This logic 
model helps in understanding various components of the 
planned intervention, the resources in place, and sensi-
tises us to potential interaction between these to produce 
the change. It also helps us to consider unintended influ-
ences on the trial results.15
study design and sample
The process evaluation will employ qualitative methods 
of data collection and analysis and will involve semi-
structured in-depth interviews with trial participants and 
healthcare professionals. Interviewees will be recruited, 
initially, following a mixed purposive sampling strategy, 
including maximum variation, extreme or deviant case16 
and subsequently by theoretical sampling to help explore 
themes that arise during initial analysis.17 Maximum varia-
tion sampling will consider trial participants age, gender, 
treatment group, history of diabetes and cardiovascular 
diseases (CVD), income and lifestyle. Healthcare profes-
sionals will include physicians and their staff who partici-
pated in the TRIUMPH study. Interviews will be recruited 
sequentially until thematic saturation is achieved. From 
our previous experience,18 19 we anticipate achieving 
thematic saturation with 20–25 trial participant interviews 
(approximately 10–12 each treatment group) and 10–15 
health professional interviews.
The study team will include researchers with diverse 
background: AS (pharmacist, quantitative and quali-
tative researcher), TL (pharmacist, health economics 
and qualitative researcher), RW (physician, quantitative 
researcher), PG (social sciences researcher), SJ (health 
economist, quantitative and qualitative researcher) and 
AP (cardiologist, quantitative researcher), with some 
being part of the core team of TRIUMPH RCT and others 
completely independent.
data collection
Data collection will be done by means of semistructured 
in-depth interviews with individual participants and 
healthcare providers. This method has primacy over 
other qualitative methods in the context of this study 
as they allow in-depth inquiry of the phenomenon, 
ensures confidentiality of the participants and enables 
prespecified topics to be explored while permitting the 
exploration of other ideas and thoughts that may spon-
taneously arise in the conversation.20
Interviews with trial participants will begin after 
the first participant enrolled in TRIUMPH RCT has 
completed their 6-month follow-up (end of study) visit. 
Healthcare professional interviews will be conducted 
following the end of follow-up of all trial participants 
in the TRIUMPH RCT. Consenting trial participant and 
healthcare professionals will be invited to an interview 
at the trial site or other place of their choice. Staff at 
TRIUMPH RCT sites will be notified of the identity of the 
trial participants nearer her/his end of study site visit. 
On the day of end of study visit, selected participants 
will be asked to confirm their willingness to be inter-
viewed. The interviewer will discuss the objectives of the 
interview, and inform the interviewee of the potential 
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benefits and harm of participation, and provide assur-
ances of confidentially. If willing to be interviewed, the 
study coordinator will organise a private place for the 
conduct of interview. Interviews will be conducted by 
trained interviewers in appropriate local language with 
trial participants and in English with healthcare profes-
sionals. Interviewees will be informed that there are 
no right or wrong answers and they are free to express 
their views in whichever manner they may want to. The 
interviewer will follow an interview guide, structuring 
questions based on the responses of the interviewee and 
ensuring that all the key areas mentioned in the inter-
view guide are covered. Each interview is likely to last, 
on average, 30 min and will be audio recorded.
Interview guides
The research team will develop interview guides 
specific for trial participant and healthcare profes-
sional interviews. Guide development will be informed 
by the objectives of the process evaluation, a liter-
ature review of the topic under research and brain 
storming among the research team. Key areas that will 
be covered in the interview guides include views and 
experience of, the TRIUMPH RCT, triple pill and BP 
control, adherence to treatment, hypertension and 
its management in Sri Lanka and translation of the 
intervention into practice and policy. Interview guides 
will be piloted before being used for data collection. 
During the process evaluation, based on the contem-
poraneous analysis of collected data, interview guides 
will be subjected to amendments as necessary in discus-
sion with the research team.21
data management and analysis
Translation of interviews
All interviews will be transcribed verbatim. Non-English 
language interviews will then be translated to English by 
native translators. Each transcript will be then reviewed 
by the interviewers against the audio for accuracy of the 
transcription and translation. Any content which may 
reveal the identity of the interviewees will be removed 
from the transcript.
Analysis
Framework analysis, a qualitative data analysis method, 
is increasingly used across multiple disciplines: 
psychology, social and health science. It is particularly 
useful in addressing four types of research questions: 
contextual, diagnostic, evaluative and strategic.22 The 
research questions of our study fall in more than one 
of these categories. Further, the other aspects of our 
research, clearly set objectives, short time scale, makes 
framework analysis a preferred approach to data 
analysis.
Figure 1 A logic model summarising the public health problem, evidence, resources, activities and anticipated outcomes of 
TRIUMPH study.
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Each transcript will be read thoroughly by two 
researchers, for data familiarisation, before coding the 
text. Using Nvivo,23 two researchers will independently 
code the first few, same, interview transcripts. The 
team of investigators include experts from Sri Lanka to 
help understand the nuances of local language wher-
ever required. This initial coding will involve careful 
review of text, line-by-line, to generate as many relevant 
codes as possible from different perspectives without 
much regard to the objectives of the study. The two 
coders will then compare and discuss codes to develop 
a framework of codes and their categories that will be 
applied to subsequent transcripts, without any restric-
tion on generating new codes. The coding of the rest 
of the transcripts will proceed following the coding 
framework. The coding framework will be subjected 
to modification if necessary, by discussion among the 
coders, as the coding of interview transcripts proceed. 
Throughout the process of data management and anal-
ysis, researchers will draft memos of reflections, ideas 
and interpretations, and discuss them with the team to 
inform analysis.
Using Microsoft Excel, a framework matrix will 
be created with the names of the categories of codes 
as column headings and interviewee identification 
number on the rows. Each category of nodes will be 
summarised ensuring its essence is intact, and mapped 
in the matrix. From the framework matrix, we will 
compare themes across interviewees, identify patterns 
and connection between the categories, identify diver-
gent themes and generate memos of the rich descrip-
tion of the phenomena relevant to the objectives of the 
study.
PAtIEnt And PUblIC InvolvEMEnt
Patients were not involved in the design of the study. 
Although we did not have a patient partner formally 
involved, the research question and outcome measures 
were substantially informed by our former research 
about patient experience and preferences for combi-
nation CVD therapies. Results of the study will be 
disseminated to study participants through healthcare 
professionals in our research network.
EtHICs And dIssEMInAtIon
dissemination
The results of this study, including the framework matrix 
and themes arising from the interviews, will be shared 
with the individuals and institutions associated with 
this study as well as academic audiences through peer- 
reviewed publication and conference presentations.
This process evaluation will complement and add 
value to the TRIUMPH trial by providing a better 
understanding of trial results. It will provide insights 
into the relevance, usefulness and adaptability of the 
strategy into clinical practice in Sri Lanka as well as 
other low- and middle-income settings. Improvement 
in BP control is dependent on several factors related 
to patient, provider, therapy and healthcare system. 
Therefore, understanding of implementation of the 
strategy and its interaction with these factors will also 
help understand determinants of BP control.
study status
Data collection commenced in May 2017 and is likely to 
end in May 2018.
Author affiliations
1The George Institute for Global Health, University of New South Wales, Hyderabad, 
India
2The George Institute for Global Health, University of New South Wales, Sydney, 
Australia
3Department of Medical Education, Faculty of Medicine, University of Kelaniya, 
Kelaniya, Sri Lanka
4Department of Public Health, Faculty of Medicine, University of Kelaniya, Kelaniya, 
Sri Lanka
5Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of 
Kelaniya, Kelaniya, Sri Lanka
6Menzies Centre for Health Policy, Sydney Medical School, The University of Sydney, 
Camperdown, New South Wales, Australia
Contributors AS, T-LL, RW, AP, AR, SJ: conceived and designed the study. PG, 
APS, HAdeS: contributed to the design of the study and are responsible for study 
coordination. AS, T-LL: drafted the manuscript. All authors reviewed the article and 
provided approval for the final version of the manuscript submitted to the journal for 
publication.
Funding This study is funded by the National Health and Medical Research 
Council (NHMRC) Australia, (App: 1041052) through The Global Alliance for Chronic 
Diseases (GACD) Hypertension prevention and control, funding scheme. 
Competing interests George Health Enterprises, the social enterprise arm of The 
George Institute for Global Health, has received investment to develop fixed-dose 
combination products containing aspirin, statin and blood pressure lowering drugs. 
George Health Enterprises has submitted patents for low-dose blood pressure 
combinations, on which AR is listed as one of the inventors.
Patient consent Not required.
Ethics approval Ethics Review Committee, Faculty of Medicine, University of 
Kelaniya, Sri Lanka, and Ethics Review Committee (RPAH Zone), Sydney, Australia.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Chow CK, et al. Prevalence, awareness, treatment, and control of 
hypertension in rural and urban communities in high-, middle-, and 
low-income countries. JAMA 2013;310:959–68.
 2. Webster JL, Dunford EK, Hawkes C, et al. Salt reduction initiatives 
around the world. J Hypertens 2011;29:1043–50.
 3. Bhatt DL, Bakris GL. Renal denervation for resistant hypertension.  
N Engl J Med 2014;371:184.
 4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/
ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the 
prevention, detection, evaluation, and management of high blood 
pressure in adults: a report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice 
Guidelines. J Am Coll Cardiol 2017;24430.
 5. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines 
for the management of arterial hypertension: the Task Force for 
the Management of Arterial Hypertension of the European Society 
5Salam A, et al. BMJ Open 2018;8:e022317. doi:10.1136/bmjopen-2018-022317
Open access
of Hypertension (ESH) and of the European Society of Cardiology 
(ESC). Eur Heart J 2013;34:2159–219.
 6. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, 
treatment, and control of hypertension in rural and urban 
communities in high-, middle-, and low-income countries. JAMA 
2013;310:959–68.
 7. Hughes D, McGuire A. The direct costs to the NHS of discontinuing 
and switching prescriptions for hypertension. J Hum Hypertens 
1998;12:533–7.
 8. McCombs JS, Nichol MB, Newman CM, et al. The costs of 
interrupting antihypertensive drug therapy in a Medicaid population. 
Med Care 1994;32:214–26.
 9. Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to 
antihypertensive treatment. Hypertension 2017;69:1113–20.
 10. Kjeldsen SE, Julius S, Dahlöf B, et al. Physician (investigator) inertia 
in apparent treatment-resistant hypertension - insights from large 
randomized clinical trials. Lennart Hansson Memorial Lecture. Blood 
Press 2015;24:1–6.
 11. Harle CA, Harman JS, Yang S. Physician and patient characteristics 
associated with clinical inertia in blood pressure control. J Clin 
Hypertens 2013;15:820–4.
 12. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and 
effectiveness of fixed-dose combinations of antihypertensive agents: 
a meta-analysis. Hypertension 2010;55:399–407.
 13. Salam A, Webster R, Singh K, et al. TRIple pill vs usual care 
management for patients with mild-to-moderate hypertension 
(TRIUMPH): Study protocol. Am Heart J 2014;167:127–32.
 14. Webster R. Protocol changes to the TRIUMPH study. Am Heart J 
2017;191:e1.
 15. Moore GF, Audrey S, Barker M, et al. Process evaluation of 
complex interventions: Medical Research Council guidance. BMJ 
2015;350:h1258.
 16. Patton MQ. Qualitative evaluation and research methods: SAGE 
Publications, inc, 1990.
 17. Bazeley P. Qualitative data analysis: practical strategies: Sage, 2013.
 18. Salam A, Stewart F, Singh K, et al. INterpreting the Processes 
of the UMPIRE Trial (INPUT): protocol for a qualitative process 
evaluation study of a fixed-dose combination (FDC) strategy to 
improve adherence to cardiovascular medications. BMJ Open 
2013;3:e002313.
 19. Wood F, Salam A, Singh K, et al. Process evaluation of the impact 
and acceptability of a polypill for prevention of cardiovascular 
disease. BMJ Open 2015;5:e008018.
 20. Brinkmann S. Qualitative interviewing: Oxford university press, 
2013.
 21. Given LM. 100 questions (and answers) about qualitative research: 
SAGE Publications, 2015.
 22. Ritchie J, Spencer L. Qualitative data analysis for applied policy 
research. In: Michael Huberman A, Miles MB, The qualitative 
researcher’s companion: SAGE, 2002;573:305–29.
 23. QSR International Pty Ltd. NVivo qualitative data analysis software; 
version 10. Melbourne: QSR International, 2012.
